What is the SEQUOIA trial?
Answer:
The SEQUOIA trial is an international Phase III clinical study evaluating zanubrutinib, a next-generation Bruton's tyrosine kinase (BTK) inhibitor, as a first-line treatment for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers are studying how well the drug controls disease progression, how safe it is over time, and how it performs in patients with high-risk genetic abnormalities, including deletion 17p (del(17p)).